Extended-release Sodium Oxybate (Lumryz) in Spasmodic Dysphonia and Voice Tremor
Status:
NOT_YET_RECRUITING
Trial end date:
2026-07-31
Target enrollment:
Participant gender:
Summary
Using a comprehensive approach of clinico-behavioral testing and neuroimaging, the researchers will examine the clinical effects of the extended-release formulation of sodium oxybate on voice symptoms in spasmodic dysphonia in an open-label, proof-of-concept, dose-finding study.